Mitochondrial regulation of stem cell osteogenic differentiation: A key driver for bone regeneration
Abstract
Mesenchymal stem cells (MSCs) are multipotent stromal cells that serve as progenitors for connective tissue and have emerged as a crucial resource in the field of tissue engineering owing to their capacity to differentiate into multiple cell lineages. MSCs-based bone regeneration strategies hold immense therapeutic potential, yet their efficacy is critically limited by inefficient osteogenic differentiation. Mounting evidence positions mitochondria as central regulators of this process, extending beyond their traditional role as cellular powerhouses. Mitochondrial regulation not only influences the induction rate of MSCs differentiation, but also determines the differentiation pathway and the ultimate fate of the resulting cells. To date, research in bone regeneration engineering has predominantly focused on the application of stem cell-based biomaterials, with limited attention given to mitochondrial development. We aim to provide a novel research perspective for targeted mitochondrial interventions in bone regeneration engineering by elucidating the mechanisms through which mitochondria regulate osteogenic differentiation of MSCs.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.